Abstract
Background: Topical efinaconazole (EFN) shows mycologic cure (MC) of 53%-55%, complete cure (CC) of 15%-18%, and few EFN-related reactions (1.2%-5.5%) following 12-month use in patients 18-70 yrs with mild-moderate onychomycosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
